Åpne denne publikasjonen i ny fane eller vindu >>Vise andre…
2024 (engelsk)Inngår i: Journal of Alzheimer's Disease, ISSN 1387-2877, E-ISSN 1875-8908, Vol. 99, nr 3, s. 1033-1046Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
Background: Individuals with type 2 diabetes (T2D) have an increased risk of cognitive symptoms and Alzheimer's disease (AD). Mis-metabolism with aggregation of amyloid-β peptides (Aβ) play a key role in AD pathophysiology. Therefore, human studies on Aβ metabolism and T2D are warranted.
Objective: The objective of this study was to examine whether acute hyperglycemia affects plasma Aβ1-40 and Aβ1-42 concentrations in individuals with T2D and matched controls.
Methods: Ten participants with T2D and 11 controls (median age, 69 years; range, 66-72 years) underwent hyperglycemic clamp and placebo clamp (saline infusion) in a randomized order, each lasting 4 hours. Aβ1-40, Aβ1-42, and insulin-degrading enzyme (IDE) plasma concentrations were measured in blood samples taken at 0 and 4 hours of each clamp. Linear mixed-effect regression models were used to evaluate the 4-hour changes in Aβ1-40 and Aβ1-42 concentrations, adjusting for body mass index, estimated glomerular filtration rate, and 4-hour change in insulin concentration.
Results: At baseline, Aβ1-40 and Aβ1-42 concentrations did not differ between the two groups. During the hyperglycemic clamp, Aβ decreased in the control group, compared to the placebo clamp (Aβ1-40: p = 0.034, Aβ1-42: p = 0.020), IDE increased (p = 0.016) during the hyperglycemic clamp, whereas no significant changes in either Aβ or IDE was noted in the T2D group.
Conclusions: Clamp-induced hyperglycemia was associated with increased IDE levels and enhanced Aβ40 and Aβ42 clearance in controls, but not in individuals with T2D. We hypothesize that insulin-degrading enzyme was inhibited during hyperglycemic conditions in people with T2D.
sted, utgiver, år, opplag, sider
IOS Press, 2024
Emneord
Alzheimer's disease, amyloid-β, cognition, endocrinology and metabolism specialty, hyperglycemia, type 2 diabetes
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-225948 (URN)10.3233/JAD-230628 (DOI)38728183 (PubMedID)2-s2.0-85194944157 (Scopus ID)
Forskningsfinansiär
Region VästerbottenSwedish Diabetes AssociationSwedish Research Council, 2023-00356Swedish Research Council, 2022-01018Swedish Research Council, 2019-02397Swedish Research Council, 2017-00915Swedish Research Council, 2022-00732EU, Horizon Europe, 101053962Familjen Erling-Perssons StiftelseStiftelsen Gamla TjänarinnorThe Swedish Brain Foundation, FO2022-0270The Swedish Brain Foundation, FO2017-0243The Swedish Brain Foundation, ALZ2022-0006EU, Horizon 2020, 860197Alzheimerfonden, AF-930351Alzheimerfonden, AF-939721Alzheimerfonden, AF-968270
2024-06-122024-06-122024-07-02bibliografisk kontrollert